Cannabis Effects on Opioid Self-Administration
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorShanna Babalonis, PhD
About this trial
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
Eligibility criteria
Qualifiers
Participants with moderate to severe opioid use disorder who experience opioid withdrawal
No allergies or adverse reactions to cannabis or opioids
Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks
Disqualifiers
Individuals seeking treatment for opioid use disorder
Trial design
Treatments tested in this trial
- Cannabis
- Placebo Cannabis
- Intranasal Opioid Agonist
- Oral Opioid Agonist
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Shanna Babalonis, PhD
Lead sponsor
University of Kentucky
Sponsor institution
Source ClinicalTrials.gov